Reblozyl Injection, Powder, Lyophilized, For Solution
Product Images NDC 59572-711

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Reblozyl (NDC 59572-711). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celgene Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (25 mg Vial Carton)

Label for Reblozyl (luspatercept-aamt) injection 25 mg per vial, lyophilized powder for subcutaneous use. The single-dose vial is intended for reconstitution prior to administration. The label includes storage instructions, manufacturer Celgene Corporation, and Rx only designation.*

FDA Label Image

Principal Display Panel (75 mg Vial Carton)

Reblozyl 25 mg/vial packaging label for luspatercept-aamt injection, powder, lyophilized, for subcutaneous use. The label advises reconstitution with sterile water for injection prior to administration and states it is a single-dose vial, discarding any unused portion. Manufactured by Celgene Corporation, a Bristol-Myers Squibb Company, and marketed by Acceleron Pharma, Inc. Storage instructions include refrigeration at 2°C to 8°C and conditions for reconstituted solution storage.*

FDA Label Image

Reblozyl 03

Reblozyl 25 mg/vial injection, lyophilized powder for solution. The label shows subcutaneous use with instructions to reconstitute with sterile water prior to administration. Packaged as a single-dose vial with the NDC 59572-711-01, manufactured by Celgene Corporation, a Bristol Myers Squibb Company. The label includes storage instructions, ingredient details, and regulatory trademarks.*

FDA Label Image

Reblozyl 04

Label for Reblozyl (luspatercept-aamt) 75 mg per vial injection, powder lyophilized for solution, intended for subcutaneous use. The label outlines storage instructions, manufacturer Celgene Corporation, and notes joint marketing by Acceleron Pharma, Inc. It includes dose discard instructions and regulatory information.*

FDA Label Image

Reblozyl 05

Reblozyl 75 mg/vial injection, powder, lyophilized, for solution for subcutaneous use from Celgene Corporation. The carton label displays the proprietary name Reblozyl with the generic name luspatercept-aamt, dosage strength of 75 mg per vial, directions for reconstitution and subcutaneous administration, and manufacturer information including Celgene Corporation and Bristol-Myers Squibb Company.*

FDA Label Image

Reblozyl 06

Reblozyl 75 mg/vial injection powder label for subcutaneous use. The lyophilized powder requires reconstitution with sterile water before administration. Manufactured by Celgene Corporation, a Bristol-Myers Squibb company, the label includes dosage form, storage instructions, and a single-dose vial indication.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.